Capecitabine-2',3'-cyclic Carbonate is a key synthetic intermediate in the production of the oral chemotherapeutic drug capecitabine. It is a pentyl carbamate derivative of 5-fluoro-1-(tetrahydro-2-oxofuran-3,4-dioxol-4-yl)uracil, featuring a cyclic carbonate protecting group on the ribose moiety. This specific structure is strategically employed in the synthetic route to control regioselectivity and improve the overall yield of the final active pharmaceutical ingredient (API). The primary and definitive application of this compound is as a critical process intermediate in the commercial manufacturing of capecitabine, a prodrug of 5-fluorouracil (5-FU). Capecitabine itself is a widely used oral chemotherapeutic agent indicated for the treatment of colorectal cancer, breast cancer, and gastric cancer. The cyclic carbonate intermediate represents a controlled, high-purity synthetic precursor essential for ensuring the quality and consistency of the final drug substance. Due to its role in the synthesis, this compound is also relevant as a potential reference standard or process-related impurity in the quality control and analytical testing of capecitabine API. Its synthesis and handling require expertise in nucleoside chemistry and adherence to strict Good Manufacturing Practice (GMP) standards when used in pharmaceutical production.